Elotuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | SLAMF7 (CD319) |
| Clinical data | |
| Trade names | Empliciti |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
IV |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Identifiers | |
| CAS Number | 915296-00-3  |
| ATC code | none |
| IUPHAR/BPS | 8361 |
| DrugBank | DB06317  |
| UNII | 1351PE5UGS |
| Chemical data | |
| Formula | C6476H9982N1714O2016S42 |
| Molecular mass | 145.5 kg/mol |
| (what is this?) (verify) |
|
Elotuzumab (brand name Empliciti, previously known as HuLuc63) is a humanized monoclonal antibody used in relapsed multiple myeloma.[1] The package insert denotes its mechanism as a SLAMF7-directed (also known as CD 319) immunostimulatory antibody.[2]
Approvals and indications
In May 2014, it was granted "Breakthrough Therapy" designation by the FDA. [3] On November 30, 2015, FDA approved elotuzumab as a treatment for patients with multiple myeloma who have received one to three prior medications.[1] Elotuzumab was labeled for use with lenalidomide and dexamethasone. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen.[2]
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Monoclonal antibodies for tumors
- Breakthrough therapy
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
